by OSDDMalaria 86 views
Opening remarks at the Open Source Drug Discovery for Malaria meeting at The University of Sydney, February 24th 2012. Speaker is Dr Mat Todd.
Background to the meeting: http://www.thesynapticleap.org/node/390
a) The question to address is whether we can we do open drug discovery collaboratively, without patents?
b) This is a very different way of doing things, and therefore interesting in itself.
c) The shift of a lab book on a desk to one on the web is a basic one, but powerful because the internet allows unrestricted collaboration.
d) Open projects have no ownership, unlike the way we do science currently
e) Open projects have fluid composition and leadership
f) Sponsorship for this meeting came from the International Program Development Fund, The University of Sydney and the Sydney osdd project funding from the Medicines for Malaria Venture
g) Diverse participants in the meeting include Saman Habib from the OSDDm project based in India
by OSDDMalaria 52 views
Opening talk at the Open Source Drug Discovery for Malaria meeting at The University of Sydney, February 24th 2012. Speaker is Professor Mary O'Kane, NSW Chief Scientist and Engineer.
(Apologies for slight audio background noise)
Welcome to the event from the NSW Chief Scientist and Engineer. O'Kane passionate about openness in science. It is important that we try to discover new ways of doing research. There have been important moves in recent years in open innovation (e.g. prizes for the solution of big problems). Open science is different since everything is shared. Australian productivity might benefit from these new ideas, and is already investing in key infrastructure projects to make it happen.
by OSDDMalaria 45 views
Open Source Drug Discovery for Malaria meeting at The University of Sydney, February 24th 2012. Speaker is Mary Moran, Policy Cures.
(Some slight audio issues early on, and with the questions, apologies)
1) The benefits and drawbacks of patents in drug research
2) R&D in neglected tropical diseases is different because all the patents are commercially worthless
3) Governments don't like the risk associated with drug R&D and are uneasy with the prevalence of failures
4) There is a fair amount of money available for R&D in NTDs. The impact of open source is to reduce the failure rate by making sure there are lots of eyeballs on the problem. The impact would be even greater if this was tried in for-profit drug discovery.
5) R&D on drugs allows us to do something tangible in parallel with other public health interventions.
by OSDDMalaria 68 views
Open Source Drug Discovery for Malaria meeting at The University of Sydney, February 24th 2012. Speaker is Luigi Palombi, Australian National University.
1) The patent system -- the myth that it is needed for a) drug development and b) innovation.
2) Patent systems are relatively recent inventions, particularly applied to chemical entities, yet there were innovations before that.
3) The development of penicillin occurred without patents, and with significant government stimulus.
4) Open source as a way around the patent barrier.
5) The Bayh-Dole act, and the ineffectiveness of universities in exploiting their IP.
6) The very broad scope of what may be patented, and whether this a good thing.
7) How do we convince governments to fund research, and accept the risk?
8) Current issues to do with counterfeiting (Avastin) and patenting genetic information (Myriad).
by OSDDMalaria 53 views
Part of the second session at the Open Source Drug Discovery for Malaria meeting at The University of Sydney, February 24th 2012. Speaker is Richard Jefferson.
Full annotation of talk: http://www.thesynapticleap.org/node/406
1) Jefferson set up Cambia 20 years ago to change the way we solve problems, starting with biotech.
2) "Innovation Cartography" -- that the best driver to innovation is a good map.
3) Jefferson is building the Patent Lens, to allow discovery in the world's patent literature and a shifting in the demographic of problem solving. The Lens (which is currently beta) is demoed in this talk.